Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Deferred Tax: 2023-2024

Historic Long-Term Deferred Tax for ARS Pharmaceuticals (SPRY) over the last 2 years, with Dec 2024 value amounting to $36.9 million.

  • ARS Pharmaceuticals' Long-Term Deferred Tax rose 26.92% to $36.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $36.9 million, marking a year-over-year increase of 26.92%. This contributed to the annual value of $36.9 million for FY2024, which is 26.92% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $36.9 million for FY2024, which was up 26.92% from $29.0 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $36.9 million in FY2024 and a low of $29.0 million during FY2023.
  • Its 2-year average for Long-Term Deferred Tax is $33.0 million, with a median of $33.0 million in 2023.
  • Data for ARS Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY grew of 26.92% (in 2024) over the last 5 years.
  • ARS Pharmaceuticals' Long-Term Deferred Tax (Yearly) stood at $29.0 million in 2023, then grew by 26.92% to $36.9 million in 2024.